company background image
HUMA

Humacyte NasdaqGS:HUMA Stock Report

Last Price

US$3.08

Market Cap

US$317.6m

7D

10.8%

1Y

-41.0%

Updated

03 Feb, 2023

Data

Company Financials +

HUMA Stock Overview

Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas.

HUMA fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance3/6
Financial Health3/6
Dividends0/6

My Notes

New

Notes are coming soon

Humacyte, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Humacyte
Historical stock prices
Current Share PriceUS$3.08
52 Week HighUS$8.04
52 Week LowUS$1.96
Beta1.13
1 Month Change43.93%
3 Month Change-6.38%
1 Year Change-41.00%
3 Year Changen/a
5 Year Changen/a
Change since IPO-68.15%

Recent News & Updates

Recent updates

Humacyte: Intriguing Potential

Oct 13

Humacyte GAAP EPS of $0.35, revenue of $1.3M

Aug 12

Shareholder Returns

HUMAUS BiotechsUS Market
7D10.8%-0.8%2.9%
1Y-41.0%4.5%-8.5%

Return vs Industry: HUMA underperformed the US Biotechs industry which returned 5.3% over the past year.

Return vs Market: HUMA underperformed the US Market which returned -9.1% over the past year.

Price Volatility

Is HUMA's price volatile compared to industry and market?
HUMA volatility
HUMA Average Weekly Movement10.2%
Biotechs Industry Average Movement12.2%
Market Average Movement6.8%
10% most volatile stocks in US Market17.6%
10% least volatile stocks in US Market2.8%

Stable Share Price: HUMA is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 10% a week.

Volatility Over Time: HUMA's weekly volatility (10%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2004146Laura Niklasonhttps://www.humacyte.com

Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs). Its investigational HAVs are designed to be easily implanted into any patient without inducing a foreign body response or leading to immune rejection.

Humacyte, Inc. Fundamentals Summary

How do Humacyte's earnings and revenue compare to its market cap?
HUMA fundamental statistics
Market CapUS$317.60m
Earnings (TTM)US$34.34m
Revenue (TTM)US$1.74m

9.2x

P/E Ratio

182.3x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
HUMA income statement (TTM)
RevenueUS$1.74m
Cost of RevenueUS$64.55m
Gross Profit-US$62.81m
Other Expenses-US$97.15m
EarningsUS$34.34m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)0.33
Gross Margin-3,605.68%
Net Profit Margin1,971.30%
Debt/Equity Ratio24.1%

How did HUMA perform over the long term?

See historical performance and comparison